1. A. As used in this section:

   1. 1. “Emergency opioid antagonist” means a drug including, but not limited to, naloxone that blocks the effects of opioids and that is approved by the United States Food and Drug Administration for the treatment of an opioid overdose; and
   2. 2. “Person” means, unless the context otherwise requires, any individual, partnership, association, corporation, limited liability company, governmental entity, tribal entity, public or private institution of postsecondary education, or other legal entity.

2. B. Notwithstanding any provision of law to the contrary, any person may:

   1. 1. Possess and store emergency opioid antagonists;
   2. 2. Acquire emergency opioid antagonists by purchase or donation;
   3. 3. Distribute or make emergency opioid antagonists available to any person to the extent permitted under applicable federal law; and
   4. 4. Administer an emergency opioid antagonist to any person who the person believes, in good faith, is experiencing an opioid overdose.
3. C. A person shall not be subject to criminal prosecution for possessing, storing, acquiring, distributing, making available, or administering emergency opioid antagonists pursuant to this section.
4. D. Any person who, in good faith, distributes, makes available, or administers emergency opioid antagonists pursuant to this section shall not be liable for any civil damages as a result of any acts or omissions by such person, except for acts or omissions constituting gross negligence or willful or wanton wrongs in distributing, making available, or administering emergency opioid antagonists.

Laws 2026, SB 65, c. 367, § 1, emerg. eff. July 1, 2026.